From MDR to NMPA: A Strategic Guide to China Market Entry

This episode details the strategic process for transitioning a medical device with a European CE mark under MDR to achieve Class II or III registration with China's NMPA. We break down the unique requirements, from local representation to in-country testing and clinical evaluation pathways, providing a clear roadmap for manufacturers looking to enter the complex but lucrative Chinese market. Key Questions: • Is a CE mark sufficient for selling a medical device in China? • What is a Product Technical Requirement (PTR) and why is it essential for NMPA registration? • Can we use our existing EU clinical data for the Chinese submission? • What are the mandatory in-country testing requirements in China? • How long does the NMPA approval process typically take for Class II and III devices? • What is the role of a mandatory China Agent in the registration process? • Can our device qualify for an exemption from clinical trials in China? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.